Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | POLA1 | P09884 | 2/20 | 0.47 |
| ▸ | POLG | P54098 | 2/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.43 |
| ▸ | PNP | P00491 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328244 | 0.90 | FGFR1 (0.57) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL2734580 | 0.90 | POLB (0.47) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL2734837 | 0.85 | POLB (0.49) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL2607253 | 0.85 | SLC22A6 (0.62) | FGFR1SLC22A6POLBPOLA1POLG | |
| Pmedap SCHEMBL29571667 | 0.85 | FGFR1 (0.72) | FGFR1SLC22A6POLBPOLA1POLG | |
| Pmedap SCHEMBL215611 | 0.85 | FGFR1 (0.72) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL1566036 | 0.84 | FGFR1 (0.63) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL30759944 | 0.84 | FGFR1 (0.63) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL30824623 | 0.83 | FGFR1 (0.60) | FGFR1SLC22A6POLBPOLA1POLG | |
| SCHEMBL1567494 | 0.83 | FGFR1 (0.60) | FGFR1SLC22A6POLBPOLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2204374-B1 | Nucleoside phosphonates and analogs thereof for the treatment of HPV-infections | GILEAD SCIENCES INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8088754-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1716162-B1 | PHOSPHONATES, MONOPHOSPHONAMIDATES, BISPHOSPHONAMIDATES FOR THE TREATMENT OF VIRAL DISEASES | GILEAD SCIENCES INC (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2204374-A1 | Nucleoside phosphonates and analogs thereof for the treatment of HPV-infections | GILEAD SCIENCES, INC. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100137240-A1 | USE OF NUCLEOSIDE DERIVATIVES AS ANTI-KOI HERPES VIRUS IN FISH | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-06-03 | — | — | US | disclosed |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2007002912-A2 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002808-A1 | ANTI-NONMELANOMA CARCINOMA COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006114065-A2 | USE OF COMPOUNDS TO INHIBIT NEOPLASIA | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY A CADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | FGFR1 1503/4885SLC22A6 3330/4885POLB 82/4885 |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | FGFR1 1503/4885SLC22A6 3330/4885POLB 82/4885 |
| US-20100137240-A1 | USE OF NUCLEOSIDE DERIVATIVES AS ANTI-KOI HERPES VIRUS IN FISH | TK1, PIGO, NME1 | FGFR1 2042/4885SLC22A6 2311/4885POLB 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.